At a glance
ClinicalIndex Comparison RecordN/ACompleted· 4,485 enrolled
Drug / intervention
Infliximabbiological
Likely dose
Infliximab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance Study of the Labeled Use of Remicade® (Infliximab) in Patients With Chronic Inflammatory Diseases
In Brief
An observational study evaluating Infliximab for Arthritis, Rheumatoid and 4 related conditions. Completed, enrolled 4,485 participants.
Detailed Summary
This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists, gastroenterologists, and dermatologists.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Psoriasis, Crohn's Disease
Countries--
CollaboratorsCentocor, Inc.
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedAug 2008
Primary CompletionAug 2011
TodayJul 2026
First PostedAug 1, 2008
Enrollment StartFeb 1, 2006
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 17.9 years ago
Interventions
Infliximabbiological
Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.